1. Scrip
  2. >>R&D
  3. >>Clinical Trials

MyoKardia Readies First-Ever Hypertrophic Cardiomyopathy Drug For US Filing

 
• By Mandy Jackson

The Phase III EXPLORER-HCM trial evaluating mavacamten in obstructive hypertrophic cardiomyopathy (oHCM) succeeded on all primary and secondary endpoints.

heart surround with pharmaceutical medicine pills and tablets, a flask and a pill box on blue background, heart health and treatment. top view. health concept
MyoKardia's once-daily pill bested placebo on all efficacy measures • Source: Shutterstock

MyoKardia Inc. plans to file mavacamten with the US Food and Drug Administration in the first quarter of 2021 based on results from the Phase III EXPLORER-HCM clinical trial in obstructive hypertrophic cardiomyopathy (oHCM). The company reported on 11 May that patients treated with the oral drug were less likely to experience shortness of breath than those who received placebo in the pivotal trial, and half of the patients treated with mavacamten were deemed asymptomatic by the end of the study.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

UK Promises To ‘Turbo-Charge’ Clinical Trials As Tariff Threat Remains

 
• By Andrew McConaghie

Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.

PureTech Weighs Up Pros And Cons Of Going Private

 
• By Kevin Grogan

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By Kevin Grogan

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.

More from R&D

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 
• By Andrew McConaghie

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By Kevin Grogan

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.

What Is Fuelling Cell And Gene Therapies In India?

 
• By Vibha Ravi

Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?